<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00950677</url>
  </required_header>
  <id_info>
    <org_study_id>H-22439</org_study_id>
    <secondary_id>K23DK075931</secondary_id>
    <nct_id>NCT00950677</nct_id>
  </id_info>
  <brief_title>The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes</brief_title>
  <acronym>T2DM</acronym>
  <official_title>The Effect of the Glucagon Suppressors Pramlintide and Exenatide on Postprandial Glucose Metabolism in Children With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if giving study drugs before a meal may lower blood&#xD;
      sugars after the meal. An improvement in blood sugar control may prevent long-term problems&#xD;
      of diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A large study in people with type 2 diabetes (T2DM) showed that lowering blood sugars stopped&#xD;
      or delayed the occurrence of health problems. As a result of the study, treatment should try&#xD;
      to control blood sugars as near to normal as safely possible.&#xD;
&#xD;
      In people without diabetes, the &quot;after meal&quot; blood sugar level is very carefully controlled&#xD;
      by several hormones. Insulin (the hormone that lowers blood sugar) and glucagon (hormone that&#xD;
      raises blood sugar) play a key role in keeping this careful balance. Also, we now know of 2&#xD;
      new substances made by the body called amylin and GLP-1 that also help with this careful&#xD;
      balance. Amylin is made in the pancreas. GLP-1 is made in the gut. We know that both amylin&#xD;
      and GLP-1 are abnormal in people with diabetes.&#xD;
&#xD;
      There are two medicines that may help to control after meal blood sugars from going too high.&#xD;
      The medicines are called Symlin (pramlintide) and Byetta (exenatide). Symlin works like&#xD;
      amylin. Byetta works like GLP-1. Both medications are very similar in the ways that they work&#xD;
      to control blood sugars.&#xD;
&#xD;
      Both medicines help to keep glucagon lower after a meal. They both also help the stomach to&#xD;
      digest food more slowly so the blood sugar does not go up too fast after eating. They also&#xD;
      help to control how much hunger a person may have before meals. This may help a person to eat&#xD;
      less and possibly lose weight. Byetta also seems to help islet cells (cells that make&#xD;
      insulin) make more insulin.&#xD;
&#xD;
      Byetta and Symlin are FDA approved for use in adults with T2DM. We want to study these drugs&#xD;
      in children with T2DM.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose</measure>
    <time_frame>4 hours</time_frame>
    <description>concentration and AUC calculations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>glucagon</measure>
    <time_frame>4 hrours</time_frame>
    <description>concentration and AUC calculations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gastric emptying</measure>
    <time_frame>4 hours</time_frame>
    <description>concentration and AUC calculations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pramlintide concentrations</measure>
    <time_frame>4 hours</time_frame>
    <description>concentration and AUC calculations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>exenatide concentrations</measure>
    <time_frame>4 hours</time_frame>
    <description>concentration and AUC calculations</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>exenatide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>exenatide one dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pramlintide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pramlintide one dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Byetta (exenatide)</intervention_name>
    <description>exenatide 5 mcg subcutaneously</description>
    <arm_group_label>exenatide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symlin (pramlintide)</intervention_name>
    <description>pramlintide 60 mcg subcutaneously</description>
    <arm_group_label>pramlintide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children with Type 2 Diabetes,&#xD;
&#xD;
          -  Between the ages of 12-21 years,&#xD;
&#xD;
          -  Tanner stage 4-5 for pubertal development,&#xD;
&#xD;
          -  Menstruating females must have a negative urine pregnancy test for inclusion,&#xD;
&#xD;
          -  Must have T2DM for at least 6 months,&#xD;
&#xD;
          -  History of negative anti-glutamic acid decarboxylase (GAD) -65 and anti-islet cell&#xD;
             antibodies,&#xD;
&#xD;
          -  HbA1c &lt; 8.5% and on a stable dose of an oral hypoglycemic agent (with or without&#xD;
             insulin) over the last 2 months, or well controlled on diet.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A history of a chronic disease other than diabetes (leukemia, asthma, inflammatory&#xD;
             bowel disease, cystic fibrosis, juvenile rheumatoid arthritis, dyslipidemia,&#xD;
             cholelithiasis etc),&#xD;
&#xD;
          -  BMI&gt; 40 kg/m2,&#xD;
&#xD;
          -  Weight of &lt; 60 kg,&#xD;
&#xD;
          -  Female with menstrual irregularities,&#xD;
&#xD;
          -  Allergy to local anesthetics (ELAMAX Cream, Ethyl Chloride),&#xD;
&#xD;
          -  Evidence or history of chemical abuse,&#xD;
&#xD;
          -  Anemia (age specific normal range for hemoglobin will be used),&#xD;
&#xD;
          -  Elevated liver enzymes (defined as more than 3 times the upper limit of the normal&#xD;
             range for age),&#xD;
&#xD;
          -  Elevated BUN or creatinine (defined as more than 3 times the upper limit of the normal&#xD;
             range for age),&#xD;
&#xD;
          -  Use of medications that may increase the blood sugars and admission to the hospital&#xD;
             for diabetes related problems over the last 6 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LUISA M RODRIGUEZ, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>July 30, 2009</study_first_submitted>
  <study_first_submitted_qc>July 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2009</study_first_posted>
  <last_update_submitted>April 21, 2017</last_update_submitted>
  <last_update_submitted_qc>April 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Luisa M. Rodriguez</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>pramlintide</keyword>
  <keyword>Symlin</keyword>
  <keyword>exenatide</keyword>
  <keyword>byetta</keyword>
  <keyword>glucagon</keyword>
  <keyword>gastric emptying</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Pramlintide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>December 4, 2020</submitted>
    <returned>December 30, 2020</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

